ALX Oncology Holdings, Inc. (ALXO)
2.00
+0.01
(+0.50%)
USD |
NASDAQ |
Aug 25, 15:02
ALX Oncology Holdings Debt to Equity Ratio : 0.0811 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0811 |
| March 31, 2026 | 0.0862 |
| December 31, 2025 | 0.5685 |
| September 30, 2025 | 0.3484 |
| June 30, 2025 | 0.2512 |
| March 31, 2025 | 0.1878 |
| December 31, 2024 | 0.1494 |
| September 30, 2024 | 0.1269 |
| June 30, 2024 | 0.1097 |
| March 31, 2024 | 0.1026 |
| December 31, 2023 | 0.0906 |
| September 30, 2023 | 0.0891 |
| June 30, 2023 | 0.0713 |
| March 31, 2023 | 0.0643 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0595 |
| September 30, 2022 | 0.023 |
| June 30, 2022 | 0.0216 |
| March 31, 2022 | 0.0169 |
| December 31, 2021 | 0.0071 |
| September 30, 2021 | 0.0072 |
| June 30, 2021 | 0.007 |
| March 31, 2021 | 0.001 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.0229 |
| June 30, 2020 | 0.0622 |
| March 31, 2020 | 0.0558 |
| December 31, 2019 | -19.64 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 160.82M |
| Total Liabilities (Quarterly) | 24.63M |
| Shareholders Equity (Quarterly) | 136.19M |
| Current Ratio | 9.709 |
| Net Debt Paydown Yield | 0.39% |